Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability. Microdeletion includes several genes: ELN encodes for elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy. The primary objective is to quantify plasma and urinary levels of elastin peptides in Williams-Beuren patients and 7q11.23 micro-duplication syndrome patients in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers) Materials and Methods: This prospective study will be carried out in Lyon at the "Hôpital Femme-Mère-Enfant" for 2 years. 3 groups of patients will be studied: Williams-Beuren patients (N=20), micro-duplication 7q11.23 syndrome patients (N=10) and healthy patients (N=60). Subjects will be followed for 1 day. Clinical examination (weight, height, blood pressure) and biological sample collection (blood and urine sample) will be carry out for Williams Beuren and micro-duplication 7q11.23 patients group. A large majority of visits will be part of patients' usual care. A large part of patients are systematically seen in consultation once a year. For healthy group, only biological sample collection will be carry out. The PE concentrations will be assessed and compared between the three groups of patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
90
Only one visit for each participant : A large majority of visits will be part of patients' usual care * Medical examination : birth, weight, gender, blood pressure, medical history * Urine and blood samples
Only one visit for each participant * Medical history * Urine and blood samples
Hôpital Femme Mère Enfant - Hospices Civils de Lyon
Bron, France
Plasma level of elastin peptides (PE)
To quantify plasma level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the blood level of PE between groups
Time frame: 1 day
Urinary level of elastin peptides (PE)
To quantify urinary level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the urinary level of PE between groups
Time frame: 1 day
Correlation between blood level of PE and cardiovascular involvement in patients.
Blood level of PE will be correlated with the presence / severity of cardiovascular disease
Time frame: 1 day
Correlation between urinary level of PE and cardiovascular involvement in patients.
Urinary level of PE will be correlated with the presence / severity of cardiovascular disease
Time frame: 1 day
Blood level of PE in treated and untreated minoxidil patients
Blood levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study
Time frame: 1 day
Urinary level of PE in treated and untreated minoxidil patients
Urinary levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.